# Rare genetic variants influence regional cortical and subcortical grey matter volumes in genetic frontotemporal dementia: A GENFI Study

**Authors:** Saira S. Mirza, Maurice Pasternak, Andrew D. Paterson, Carmela Tartaglia, Sandra E. Black, Sara Mitchell, Morris Freedman, David F. Tang‐Wai, Ekaterina Rogaeva, David M Cash, Martina Bocchetta, John van Swieten, Robert Laforce, Fabrizio Tagliavini, Barbara Borroni, Daniela Galimberti, James B Rowe, Caroline Graff, Elizabeth Finger, Sandro Sorbi, Alexandre Mendonca, Christopher R. Butler, Alexander Gerhard, Raquel Sánchez‐Valle, Fermin Moreno, Matthis Synofzik, Rik Vandenberghe, Simon Ducharme, Johannes Levin, Markus Otto, Isabel Santana, Jonathan D. Rohrer, Mario Masellis

PMC · DOI: 10.1002/alz70856_106121 · Alzheimer's & Dementia · 2026-01-08

## TL;DR

This study finds that rare genetic variants can affect brain structure in people with genetic frontotemporal dementia.

## Contribution

The study identifies rare genetic variants that influence brain volume in genetic frontotemporal dementia patients.

## Key findings

- Rare genetic variants are linked to changes in grey matter volumes in the temporal lobe and putamen.
- Some genes involved are related to brain development and function.
- These findings suggest potential genetic modifiers of frontotemporal dementia.

## Abstract

There is substantial heterogeneity in clinical presentation of genetic Frontotemporal Dementia (FTD), even within the same family. This suggests that additional heritability may exist and contribute to this variable presentation. We examined whether gene‐based aggregate burden of genome‐wide rare variants (minor allele frequency [MAF]: ≤1%) contribute to variation in regional cortical and subcortical grey matter volumes, after controlling for effects of causative mutations in GRN, MAPT, and C9orf72.

This study was embedded within the GENetic Frontotemporal dementia Initiative (GENFI), which recruits genetic FTD cases and their asymptomatic at‐risk family members, both carriers and non‐carriers of FTD mutations. We included 518 participants with genotype (Neurochip; imputed against TOPMed), and T1w‐MRI brain volumetric data. Gene‐based burden tests that aggregate the number of rare variants by gene were used to examine the association of rare variants (MAF: ≤1%) with regional cortical and subcortical grey matter volumes (70 regions of interest [ROIs]), controlling for age, sex, total intracranial volume, mutation status, scanner site, population stratification, and family membership (kinship matrix) using RVTests. Annotations for loss of function mutations (LOF): start gain, stop loss, start loss, essential splice site, stop gain, normal splice site, and non‐synonymous. Multiple testing correction accounted for the number of genes and number of independent grey matter volumes as calculated by matSpD (p‐value threshold: 0.05/(17,053x42) = 6.98 x10‐8).

Aggregate burden of LOF mutations (DNAJB8‐AS1, WDR26, RDM1P5, BSND, CNOT2, DDA1, ASAH2B, PPM1A, HOXD13, ALDH1A1, CENATAC, ANKRD45) was associated with significantly lower volumes within the left temporal lobe (ROIs: left temporal and lateral temporal left), and greater volume in the putamen bilaterally (TSACC). All genes are protein coding, except the DNAJB8‐AS1 (antisense RNA) and RDM1P5 (pseudogene), and are variably expressed in the brain. Molecular functions of significant genes involve regulation of gene expression, transcription, and cell cycle, ion channel function, and chromosomal segregation. WDR26 and CNOT2 genes have been implicated in neurodevelopment and neurological disorders respectively; BSND gene is involved in neurotransmission.

Identification of deleterious or protective rare variants contributing to FTD imaging phenotypes may help identify genetic modifiers of familial FTD. Replication in larger cohorts is needed.

## Linked entities

- **Genes:** GRN (granulin precursor) [NCBI Gene 2896], MAPT (microtubule associated protein tau) [NCBI Gene 4137], C9orf72 (C9orf72-SMCR8 complex subunit) [NCBI Gene 203228], DNAJB8-AS1 (DNAJB8 antisense RNA 1) [NCBI Gene 285224], WDR26 (WD repeat domain 26) [NCBI Gene 80232], RDM1P5 (RDM1 pseudogene 5) [NCBI Gene 100131347], BSND (barttin CLCNK type accessory subunit beta) [NCBI Gene 7809], CNOT2 (CCR4-NOT transcription complex subunit 2) [NCBI Gene 4848], DDA1 (DET1 and DDB1 associated 1) [NCBI Gene 79016], ASAH2B (N-acylsphingosine amidohydrolase 2B) [NCBI Gene 653308], PPM1A (protein phosphatase, Mg2+/Mn2+ dependent 1A) [NCBI Gene 5494], HOXD13 (homeobox D13) [NCBI Gene 3239], ALDH1A1 (aldehyde dehydrogenase 1 family member A1) [NCBI Gene 216], CENATAC (centrosomal AT-AC splicing factor) [NCBI Gene 338657], ANKRD45 (ankyrin repeat domain 45) [NCBI Gene 339416]
- **Diseases:** Frontotemporal Dementia (MONDO:0010857)

---
Source: https://tomesphere.com/paper/PMC12782247